White House Adviser Argued With Dr. Fauci Over Anti-Malaria Drug

White House Trade and Manufacturing Policy Director Peter Navarro speaks during the daily briefing on COVID-19 at the White House on March 22, 2020. (Photo by ERIC BARADAT/AFP via Getty Images)
|
April 6, 2020 8:44 a.m.
EDITORS' NOTE: TPM is making our COVID-19 coverage free to all readers during this national health crisis. If you’d like to support TPM's reporters, editors and staff, the best way to do so is to become a member.

White House trade adviser Peter Navarro reportedly had a heated dispute with Dr. Anthony Fauci, a key member of the White House Anti-Coronavirus Task Force, over the efficacy of hydroxychloroquine, an anti-malaria drug, against COVID-19 on Saturday.

An unnamed source told Axios that Navarro had claimed the drug showed a “clear therapeutic efficacy” during a meeting in the Situation Room, prompting Fauci to point out that adviser did not have hard data on the matter.

“What are you talking about?” Fauci asked, according to CNN.

The doctor reportedly said any evidence that hydroxychloroquine would be effective was purely anecdotal, a rebuttal that infuriated Navarro.

“That’s science, not anecdote,” the adviser, who had begun raising his voice, said in response.

“There has never been a confrontation in the task force meetings like the one yesterday,” the source told Axios

Key Coronavirus Crisis Links

TPM’s COVID-19 hub.
Josh Marshall’s Twitter List of Trusted Experts (Epidemiologists, Researchers, Clinicians, Journalists, Government Agencies) providing reliable real-time information on the COVID-19 Crisis.
COVID-19 Tracking Project (updated data on testing and infections in the U.S.).
Johns Hopkins Global COVID-19 Survey (most up to date numbers globally and for countries around the world).
Worldometers.info (extensive source of information and data visualizations on COVID-19 Crisis — discussion of data here).
Comments
advertisement
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Senior Editor:
Special Projects Editor:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Publishing Associate:
Front-End Developer:
Senior Designer:
SPECIAL DEAL FOR PAST TPM MEMBERS
40% OFF AN ANNUAL PRIME MEMBERSHIP
REJOIN FOR JUST $30